Shortly afterward, the team published another study that demonstrated that in BRAF-mutated melanoma cell lines that had developed resistance to BRAF inhibitors, the use of cabotegravir or doravirine could suppress HERV-K activity, reverse the BRAF-inhibitor-induced upregulation of HERV-K, and induce apoptosis in drug-resistant tumor cells [162], providing new avenues for developing combination therapies. This evidence concerns the gene BRAF and melanoma.